Opioid-Based Haptens: Development of Immunotherapy

Abstract

Over the past decades, extensive preclinical research has been conducted to develop vaccinations to protect against substance use disorder caused by opioids, nicotine, cocaine, and designer drugs. Morphine or fentanyl derivatives are small molecules, and these compounds are not immunogenic, but when conjugated as haptens to a carrier protein will elicit the production of antibodies capable of reacting specifically with the unconjugated hapten or its parent compound. The position of the attachment in opioid haptens to the carrier protein will influence the specificity of the antiserum produced in immunized animals with the hapten-carrier conjugate. Immunoassays for the determination of opioid drugs are based on the ability of drugs to inhibit the reaction between drug-specific antibodies and the corresponding drug-carrier conjugate or the corresponding labelled hapten. Pharmacological studies of the hapten-carrier conjugates resulted in the development of vaccines for treating opioid use disorders (OUDs). Immunotherapy for opioid addiction includes the induction of anti-drug vaccines which are composed of a hapten, a carrier protein, and adjuvants. In this review we survey the design of opioid haptens, the development of the opioid radioimmunoassay, and the results of immunotherapy for OUDs.

Keywords: fentanyl; hapten; heroin; immunotherapy; morphine; opioid; oxycodone; vaccination.

Figure 1

Morphine-based immunisation or vaccination proposed for the treatment of OUD.

Figure 2

Structures of morphine-based haptens and immunoconjugates (2, 5, 19 and 20).

Figure 3

The bioconjugate structure of 2-arylazomorphine-BSA, adopted from Catlin et al. [24].

Scheme 1

Synthesis of morphine-6-hemisuccinyl-bovine serum albumin conjugate.

Scheme 2

Maleimide-BSA– conjugate.

Scheme 3

Functionalizing nor-compounds into carboxymethyl derivatives.

Scheme 4

Functionalizing nor-compounds into carboxyethyl derivatives.

Scheme 5

3-O-functionalized haptens.